Home News Insights Trading halts Paper trading Guide Community My account

Market calendarChecking market schedule

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Copyright © WAPE. All rights reserved.

Loading news article.

BioMarin Seeks to Strengthen Market Position in Rare Bone Disease Treatment | WAPE

Newsbenzinga

BioMarin Seeks to Strengthen Market Position in Rare Bone Disease Treatment

Aug 18, 2026, 13:37 ET · Published

Article summary

BioMarin Pharmaceutical agrees to acquire Alesta Therapeutics for $275 million upfront, securing ALE1 for rare bone disease treatment.

An excerpt from the original article.

Related companies

AZNAZNView stock

Comments —

Comment

Loading comments…